MedTrace Logo

Mesenchymal Stem Cell Transplantation for Osteoarthritis

NCT03969680 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-01-24

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BMSCs) plus autologous platelet rich plasma (PRP) in the treatment of severe knee osteoarthritis.

Conditions

Interventions

BIOLOGICAL

Auotologous BMSCs plus autologous PRP

30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.

BIOLOGICAL

Auotologous PRP

30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.

Sponsors & Collaborators

  • Yantai Yuhuangding Hospital

    lead OTHER

Principal Investigators

  • Peiwen Lian, PhD · Yantai Yuhuangding Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-08
Primary Completion
2023-10-30
Completion
2023-12-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03969680 on ClinicalTrials.gov